Published in Hum Antibodies on January 01, 2004
An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med (2012) 2.10
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun (2006) 1.59
Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun (2007) 1.40
Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun (2006) 1.38
Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun (2007) 1.37
Monoclonal antibody therapies against anthrax. Toxins (Basel) (2011) 1.19
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol (2009) 1.11
Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin Vaccine Immunol (2006) 1.04
Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J Infect Dis (2010) 1.01
Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) (2011) 0.99
Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis. Open Microbiol J (2010) 0.98
Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment. Clin Vaccine Immunol (2012) 0.95
Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine (2012) 0.91
Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg Med Chem (2007) 0.89
An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis. Expert Opin Investig Drugs (2015) 0.80
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS (2007) 1.99
Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein region. Genetics (2010) 1.61
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun (2006) 1.59
Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines (2004) 1.46
Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci U S A (2008) 1.43
Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res (2007) 1.19
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol (2011) 1.12
Evolution of CCR5 use before and during coreceptor switching. J Virol (2008) 1.09
Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett (2012) 1.04
Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malar J (2004) 1.01
IgG(4) Pf NPNA-1 a human anti-Plasmodium falciparum sporozoite monoclonal antibody cloned from a protected individual inhibits parasite invasion of hepatocytes. Hum Antibodies (2004) 0.95
Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching. J Virol (2007) 0.93
Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr (2011) 0.88
Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations. J Virol (2007) 0.86
Trypanosoma cruzi: synergistic cytotoxicity of multiple amphipathic anti-microbial peptides to T. cruzi and potential bacterial hosts. Exp Parasitol (2010) 0.84
CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity. J Virol (2012) 0.83
Module based antibody engineering: a novel synthetic REDantibody. J Immunol Methods (2010) 0.82
Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm. BMC Biotechnol (2011) 0.80
Cognate peptide-receptor ligand mapping by directed phage display. Proteome Sci (2005) 0.79
Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. Hum Antibodies (2012) 0.77
Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins. Sci Rep (2013) 0.77
Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals. Malar J (2009) 0.77
Ribosome display of combinatorial antibody libraries derived from mice immunized with heat-killed Xylella fastidiosa and the selection of MopB-specific single-chain antibodies. Appl Environ Microbiol (2012) 0.77